Fundamental analysis · SEC EDGAR · TTM through 28/03/2026
MDLN · Nasdaq · Healthcare
Fundamental quality
48
out of 100
Source: SEC EDGAR · TTM through 28/03/2026
The score combines growth, profitability and financial strength. Here its profitability weighs in its favor, while its growth drags it down the most.
| Year | Revenue | Net income | Free cash flow | Net debt |
|---|---|---|---|---|
| 2023 | 23,231 | 234 | 1,410 | — |
| 2024 | 25,507 | 1,163 | 1,415 | 16,293 |
| 2025 | 28,432 | 1,159 | 1,297 | 10,621 |
Between 2023 and 2025, revenue went from $23,231M to $28,432M (+22%) and net income went from $234M to $1,159M (+395%).
Annual figures in millions of U.S. dollars ($M) per SEC filings. Net debt is total debt minus cash.
Is Medline Inc. a profitable company?
Medline Inc. is profitable, with a net margin of 3.7%, though a thin one.
Does Medline Inc. have a lot of debt?
Yes, its leverage is high: net debt is 3.35 times its EBITDA.
Is Medline Inc. growing?
Its revenue has grown 11.5% annualized in recent years.
Does Medline Inc. generate cash?
Yes. It converts about 3.5% of its revenue into free cash flow.
The thresholds are general and the system doesn't judge qualitative factors. See the full methodology and use this analysis as a first filter, never as a final decision.
Is Medline Inc. cheap or expensive?
That depends on the current price. Look it up, enter it in the tool and get the full valuation verdict (P/E against its sector).
Compute the valuation →Brokers you can use to invest in U.S. and European stocks.
The serious investor's standard →
Popular in the U.S. →
Other analyses
NVIDIA (NVDA) · Microsoft (MSFT) · Apple (AAPL) · Alphabet (Google) (GOOGL) · Amazon (AMZN) · Meta Platforms (META) · see more →